arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Caribou Biosciences, Inc.

CRBU
$1.64 0.00 (0.00%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Caribou Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $157.2M
Dividend Yield
Revenue Growth 1.9%
Op. Margin None
ROIC -20.4%
FCF / Share $-0.28
Trailing P/E
Price / Book 1.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.40M
↑ +1.9%
Net Income Profit after all expenses
$-25.09M
↑ +37.3%
Operating Margin Operating profit as % of sales
-61.8%
↑ +86.8%
FCF / Share Free cash flow per share
$-0.28
↑ +30.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
7
Cash Quality
51

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters